Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
University of Medicine and Dentistry of New Jersey
Rutgers, The State University of New Jersey
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease.
Confirmation of diagnosis must be performed at MSKCC.
Patient's liver metastases must be deemed unresectable and comprise \<70% of the liver parenchyma.
A patient may have had prior chemotherapy or be previously untreated.
Patient may not have received prior treatment with FUDR or \>2 doses of Oxaliplatin.
KPS \> or = to 60%.
WBC \> or = to 3,000 cells/mm3 and platelet count \> or = to 100,000 cells/mm3 within 14 days of registration.
Creatinine \< or = to 1.5 mg/dl within 14 days of registration.
Total serum bilirubin \< or = 2.0 mg/dl within 14 days of registration.
You may not be if
No active concurrent malignancies: except a patient's potentially resectable colorectal primary.
Patient must not have obstruction of GI or GU tract.
Patient must not have current, symptomatic peripheral sensory neuropathy.
No prior radiation to liver.
No active infection, ascites, or hepatic encephalopathy.
Age ≥ 18 years.
Female patients cannot be pregnant or lactating.
Signed informed consent.
Clareo Health | Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer
